These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9794454)

  • 21. GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro.
    Gelling RW; Coy DH; Pederson RA; Wheeler MB; Hinke S; Kwan T; McIntosh CH
    Regul Pept; 1997 Apr; 69(3):151-4. PubMed ID: 9226399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo.
    Gault VA; Parker JC; Harriott P; Flatt PR; O'Harte FP
    J Endocrinol; 2002 Nov; 175(2):525-33. PubMed ID: 12429050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
    Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide.
    Kerr BD; Flatt AJ; Flatt PR; Gault VA
    Biochem Biophys Res Commun; 2011 Jan; 404(3):870-6. PubMed ID: 21184739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: wortmannin-sensitive inhibition by insulin.
    McIntosh CH; Bremsak I; Lynn FC; Gill R; Hinke SA; Gelling R; Nian C; McKnight G; Jaspers S; Pederson RA
    Endocrinology; 1999 Jan; 140(1):398-404. PubMed ID: 9886851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
    McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
    J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
    Bhat VK; Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo.
    Nakamura T; Tanimoto H; Mizuno Y; Tsubamoto Y; Noda H
    Diabetes Obes Metab; 2012 Jun; 14(6):511-7. PubMed ID: 22192426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impairment of the insulinotropic effect of gastric inhibitory polypeptide (GIP) in obese and diabetic rats is related to the down-regulation of its pancreatic receptors.
    Younan SM; Rashed LA
    Gen Physiol Biophys; 2007 Sep; 26(3):181-93. PubMed ID: 18063845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GIP(3-30)NH
    Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets.
    Zhou J; Livak MF; Bernier M; Muller DC; Carlson OD; Elahi D; Maudsley S; Egan JM
    Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E538-47. PubMed ID: 17505054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor.
    Gremlich S; Porret A; Hani EH; Cherif D; Vionnet N; Froguel P; Thorens B
    Diabetes; 1995 Oct; 44(10):1202-8. PubMed ID: 7556958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conformational, receptor interaction and alanine scan studies of glucose-dependent insulinotropic polypeptide.
    Venneti KC; Malthouse JP; O'Harte FP; Hewage CM
    Biochim Biophys Acta; 2011 Jul; 1814(7):882-8. PubMed ID: 21539943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GIP(3-30)NH
    Sparre-Ulrich AH; Gabe MN; Gasbjerg LS; Christiansen CB; Svendsen B; Hartmann B; Holst JJ; Rosenkilde MM
    Biochem Pharmacol; 2017 May; 131():78-88. PubMed ID: 28237651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model.
    Weaver RE; Donnelly D; Wabitsch M; Grant PJ; Balmforth AJ
    Int J Obes (Lond); 2008 Nov; 32(11):1705-11. PubMed ID: 18779825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.
    Gault VA; Flatt PR; Bailey CJ; Harriott P; Greer B; Mooney MH; O'harte FP
    Biochem J; 2002 Nov; 367(Pt 3):913-20. PubMed ID: 12150711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coingestion of acylglycerols differentially affects glucose-induced insulin secretion via glucose-dependent insulinotropic polypeptide in C57BL/6J mice.
    Shimotoyodome A; Fukuoka D; Suzuki J; Fujii Y; Mizuno T; Meguro S; Tokimitsu I; Hase T
    Endocrinology; 2009 May; 150(5):2118-26. PubMed ID: 19179446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The equine glucose-dependent insulinotropic polypeptide receptor: A potential therapeutic target for insulin dysregulation.
    Kheder MH; Sillence MN; Bryant LM; de Laat MA
    J Anim Sci; 2017 Jun; 95(6):2509-2516. PubMed ID: 28727072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.
    O'Harte FP; Gault VA; Parker JC; Harriott P; Mooney MH; Bailey CJ; Flatt PR
    Diabetologia; 2002 Sep; 45(9):1281-91. PubMed ID: 12242461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expression and function of glucose-dependent insulinotropic polypeptide in the embryonic mouse pancreas.
    Prasadan K; Koizumi M; Tulachan S; Shiota C; Lath N; Paredes J; Guo P; El-Gohary Y; Malek M; Shah S; Gittes GK
    Diabetes; 2011 Feb; 60(2):548-54. PubMed ID: 21270265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.